Floatz logo

Glofitamab

Relapsed /Refractory DLBCL

Olivia Newton-John Cancer Research InstitutePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

107 Active assets in the Relapsed /Refractory DLBCL cohort.

Asset / SponsorPhaseRating
Selinexor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3BB
DEXAMETHASONE
City of Hope Medical Center
Phase 2/3BB
Axicabtagene Ciloleucel
Zhujiang Hospital
Phase 3BB
Ifosfamide
University of California, Davis
Phase 3BB
ETOPOSIDE
University of California, Davis
Phase 3BB

View all 50 →

Same molecule, other indications

Glofitamab is also rated in:

B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →